Related Experiment Video
Updated: May 9, 2026
09:35
A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia
Published on: November 15, 2024
Association between transforming growth factor-beta 1 T869C polymorphism and ischemic stroke: a meta-analysis
Lingmei Peng1, Peng Li, Jian Chen
1The National Key Clinic Specialty, The Neurosurgery Institute of Guangdong Province, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Plos One
|July 18, 2013
Summary
This meta-analysis found no significant association between transforming growth factor-beta1 (TGF-β1) T869C polymorphism and ischemic stroke (IS) risk. Current studies are inconsistent, necessitating larger, well-designed prospective research for definitive conclusions.
Area of Science:
- Genetics
- Neurology
- Epidemiology
Background:
- Transforming growth factor-beta1 (TGF-β1) plays a role in vascular remodeling and inflammation.
- The T869C polymorphism in the TGF-β1 gene has been investigated for its potential link to various diseases, including ischemic stroke (IS).
Purpose of the Study:
- To conduct a meta-analysis of published studies to explore the association between the TGF-β1 T869C polymorphism and the risk of ischemic stroke (IS).
Main Methods:
- Systematic electronic searches were performed across multiple databases (PubMed, Science Direct, BIOSIS Previews, etc.).
- Pooled odds ratios (ORs) with 95% confidence intervals (95%CIs) were calculated to assess the strength of association.
- Subgroup, sensitivity, and publication bias analyses were conducted to explore heterogeneity and ensure outcome stability.
Main Results:
- Six studies involving 1701 cases were included in the meta-analysis.
- Overall, no significant association was found between TGF-β1 T869C polymorphism and IS risk across all genetic models.
- While initial subgroup analyses by study design showed some significant associations, these became non-significant after correction for multiple testing.
Conclusions:
- Current epidemiological studies on the TGF-β1 T869C polymorphism and IS susceptibility are inconsistent.
- The small sample sizes and significant heterogeneity across studies limit definitive conclusions.
- Further large-scale, well-designed prospective studies are warranted to clarify the relationship.
Related Concept Videos
01:26Transient Ischemic Attack l: Introduction
A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...